Live-Cell Microscopy Reveals Small Molecule Inhibitor Effects on MAPK Pathway Dynamics

Oncogenic mutations in the mitogen activated protein kinase (MAPK) pathway are prevalent in human tumors, making this pathway a target of drug development efforts. Recently, ATP-competitive Raf inhibitors were shown to cause MAPK pathway activation via Raf kinase priming in wild-type BRaf cells and tumors, highlighting the need for a thorough understanding of signaling in the context of small molecule kinase inhibitors. Here, we present critical improvements in cell-line engineering and image analysis coupled with automated image acquisition that allow for the simultaneous identification of cellular localization of multiple MAPK pathway components (KRas, CRaf, Mek1 and Erk2). We use these assays in a systematic study of the effect of small molecule inhibitors across the MAPK cascade either as single agents or in combination. Both Raf inhibitor priming as well as the release from negative feedback induced by Mek and Erk inhibitors cause translocation of CRaf to the plasma membrane via mechanisms that are additive in pathway activation. Analysis of Erk activation and sub-cellular localization upon inhibitor treatments reveals differential inhibition and activation with the Raf inhibitors AZD628 and GDC0879 respectively. Since both single agent and combination studies of Raf and Mek inhibitors are currently in the clinic, our assays provide valuable insight into their effects on MAPK signaling in live cells.

[1]  J. Hancock,et al.  H-ras but Not K-ras Traffics to the Plasma Membrane through the Exocytic Pathway , 2000, Molecular and Cellular Biology.

[2]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[3]  T. Bivona,et al.  Analysis of Ras activation in living cells with GFP-RBD. , 2006, Methods in enzymology.

[4]  Patricia Greninger,et al.  A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. , 2009, Cancer cell.

[5]  S. J. Taylor,et al.  Nonradioactive determination of Ras-GTP levels using activated ras interaction assay. , 2001, Methods in enzymology.

[6]  W. Kolch,et al.  Raf-1 protein kinase is required for growth of induced NIH/3T3 cells , 1991, Nature.

[7]  S. Wiese,et al.  B- and C-RAF Display Essential Differences in Their Binding to Ras , 2007, Journal of Biological Chemistry.

[8]  Ming Zhou,et al.  Regulation of Raf-1 by direct feedback phosphorylation. , 2005, Molecular cell.

[9]  L. Maffei,et al.  Dynamic regulation of ERK2 nuclear translocation and mobility in living cells , 2006, Journal of Cell Science.

[10]  Péter Várnai,et al.  Structural determinants of Ras-Raf interaction analyzed in live cells. , 2002, Molecular biology of the cell.

[11]  Murat Cirit,et al.  Allosteric Modulation of Ras-GTP Is Linked to Signal Transduction through RAF Kinase* , 2010, The Journal of Biological Chemistry.

[12]  J. Settleman,et al.  Targeting the RAF-MEK-ERK pathway in cancer therapy. , 2009, Cancer letters.

[13]  P. Cullen,et al.  Studying the spatial and temporal regulation of Ras GTPase-activating proteins. , 2006, Methods in Enzymology.

[14]  S. Neidle,et al.  Equilibrium and Kinetic Measurements Reveal Rapidly Reversible Binding of Ras to Raf (*) , 1996, The Journal of Biological Chemistry.

[15]  Karel Svoboda,et al.  Supersensitive Ras activation in dendrites and spines revealed by two-photon fluorescence lifetime imaging , 2006, Nature Neuroscience.

[16]  Murat Cirit,et al.  Systematic Quantification of Negative Feedback Mechanisms in the Extracellular Signal-regulated Kinase (erk) Signaling Network * □ S Experimental Procedures Data-driven Modeling of Feedback Regulating Erk Signaling Data-driven Modeling of Feedback Regulating Erk Signaling Data-driven Modeling of Fee , 2022 .

[17]  J. Au,et al.  Comparison of methods for evaluating drug-drug interaction. , 2010, Frontiers in bioscience.

[18]  Boris N. Kholodenko,et al.  Signalling ballet in space and time , 2010, Nature Reviews Molecular Cell Biology.

[19]  T. Waldman,et al.  B-Raf Is Dispensable for K-Ras-Mediated Oncogenesis in Human Cancer Cells 1 , 2004, Cancer Research.

[20]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[21]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[22]  Matthew Fosbrink,et al.  Live-cell Molecular Analysis of Akt Activation Reveals Roles for Activation Loop Phosphorylation* , 2007, Journal of Biological Chemistry.

[23]  Akihiro Kusumi,et al.  Single-molecule imaging analysis of Ras activation in living cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Nils Blüthgen,et al.  How robust are switches in intracellular signaling cascades? , 2003, Journal of theoretical biology.

[25]  A. Brunet,et al.  Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts , 1993, The Journal of cell biology.

[26]  G. Schwartz,et al.  A phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (Pts) with advanced solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Toshio Yanagida,et al.  A RasGTP-induced conformational change in C-RAF is essential for accurate molecular recognition. , 2009, Biophysical journal.

[28]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[29]  A. Miyawaki,et al.  Spatio-temporal images of growth-factor-induced activation of Ras and Rap1 , 2001, Nature.

[30]  K. Flaherty,et al.  Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Suzanne Schubbert,et al.  Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.

[32]  C. Der,et al.  Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells , 2010, Journal of molecular signaling.

[33]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[34]  R. Durbin,et al.  Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes , 2010, Nature.

[35]  唐青,et al.  Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto , 2005 .

[36]  D Broek,et al.  Two types of RAS mutants that dominantly interfere with activators of RAS , 1994, Molecular and cellular biology.

[37]  Robert A. Weinberg,et al.  Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.

[38]  J. Blenis,et al.  Nuclear localization and regulation of erk- and rsk-encoded protein kinases , 1992, Molecular and cellular biology.

[39]  B. Sikic,et al.  A phase 1 dose-escalation study of XL518, a potent MEK inhibitor administered orally daily to subjects with solid tumors , 2008 .